IXICO’s Alzheimer’s Disease Footprint at a Glance

Click below to download this factsheet and share with your colleagues or network

Pioneering Precision in AD Imaging

IXICO excels in AD imaging with advanced imaging biomarkers to quantify markers such as amyloid plaques, tau tangles, and brain atrophy. Our AI-driven IXIQ.Ai platform enhances the accuracy and efficiency of brain imagine measurements. We have supported over 20,000 brain scans collected through various AD research initiatives, driving innovation and harmonizing imaging data for better clinical trial outcomes.

Seamless Global Imaging Solutions

We offer comprehensive imaging support with global site management, a regulatory-compliant platform and processes, and rapid Amyloid and Tau PET eligibility read reports within three days. Our services include centralized radiology reads, AD-specific workflows, advanced analytics, and tailored solutions to meet diverse clinical trial needs, ensuring seamless data collection and analysis.

Proven Excellence in AD Clinical Trials

With over 25 sponsors supported across 55 clinical studies, IXICO collaborates with leading institutions and initiatives like ADNI, GAP, AMYPAD and EPAD to name a few. Our proven expertise ensures high-quality deliverables and successful trial outcomes, making us a trusted partner in advancing AD research and clinical trials.

 

Download

---